- Home
- LUCD vs SEER Comparison
LUCD vs SEER Comparison
Compare LUCD & SEER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- SEER
- Stock Information
- Founded
- LUCD 2018
- SEER 2017
- Country
- LUCD United States
- SEER United States
- Employees
- LUCD N/A
- SEER N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- SEER Medicinal Chemicals and Botanical Products
- Sector
- LUCD Health Care
- SEER Health Care
- Exchange
- LUCD Nasdaq
- SEER Nasdaq
- Market Cap
- LUCD 112.5M
- SEER 125.3M
- IPO Year
- LUCD 2021
- SEER 2020
- Fundamental
- Price
- LUCD $1.02
- SEER $2.07
- Analyst Decision
- LUCD Strong Buy
- SEER Hold
- Analyst Count
- LUCD 4
- SEER 1
- Target Price
- LUCD $3.94
- SEER $3.00
- AVG Volume (30 Days)
- LUCD 704.2K
- SEER 123.7K
- Earning Date
- LUCD 08-13-2025
- SEER 08-06-2025
- Dividend Yield
- LUCD N/A
- SEER N/A
- EPS Growth
- LUCD N/A
- SEER N/A
- EPS
- LUCD N/A
- SEER N/A
- Revenue
- LUCD $4,360,000.00
- SEER $16,288,000.00
- Revenue This Year
- LUCD $49.70
- SEER $27.05
- Revenue Next Year
- LUCD $198.20
- SEER $28.33
- P/E Ratio
- LUCD N/A
- SEER N/A
- Revenue Growth
- LUCD 14.74
- SEER 10.52
- 52 Week Low
- LUCD $0.73
- SEER $1.59
- 52 Week High
- LUCD $1.80
- SEER $2.63
- Technical
- Relative Strength Index (RSI)
- LUCD 44.17
- SEER 44.61
- Support Level
- LUCD $0.96
- SEER $1.97
- Resistance Level
- LUCD $1.03
- SEER $2.23
- Average True Range (ATR)
- LUCD 0.06
- SEER 0.08
- MACD
- LUCD 0.00
- SEER -0.01
- Stochastic Oscillator
- LUCD 43.75
- SEER 30.30
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.